<DOC>
	<DOCNO>NCT02667106</DOCNO>
	<brief_summary>This Phase I study examine systemic pharmacokinetics RX0041-002 follow acute , topical , intranasal administration healthy male female volunteer .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Study RX0041-2</brief_title>
	<detailed_description>This Phase I , single dose , single-center , open-label study plasma urinary pharmacokinetics RX004-002 major metabolite male female healthy subject .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<criteria>1 . Male female ≥18 ≤ 80 year age time dose . 2 . BMI ≥ 18 ≤ 32 screen visit . 3 . Females ( childbearing potential sexually active ) male ( sexually active partner childbearing potential ) agree use medically acceptable effective birth control method first dose 8 day follow administration study drug . Medically acceptable method contraception may use participant and/or his/her partner include abstinence , birth control pills patch , diaphragm , intrauterine device ( IUD ) , condom , surgical sterilization , progestin implant injection . Prohibited method include : rhythm method withdrawal . 4 . Willing able provide write informed consent able understand comply protocol requirement . 5 . During period study confinement , subject require abstain beverage contain grapefruit juice caffeine . 1 . Has know allergy ester base anesthetic include cocaine HCl , procaine , tetracaine , chloroprocaine , dibucaine , benzocaine Amide base anesthetic allergy NOT exclusionary . Amide base anesthetic : Lidocaine , mepivicaine , bupivicaine , levobupivicaine , ropivicaine , etidocaine , prilocaine , articaine . 2 . The use amphetamine , methylphenidate stimulant prescription nonprescription product pseudoephedrine , bronchial inhaler contain sympathomimetics ( epinephrine betareceptor agonist ) herbal product 7 day prior screen need use drug course study . 3 . Use SNRIs/SSRIs antidepressant tricyclic antidepressant to7 day 5 halflives ( whichever longer ) prior screen need use drug screen period throughout time period trial . 4 . Use MAO Inhibitor drug to14 day prior screen need use drug screen period throughout time period trial . 5 . Has history abuse control substance , nasal otherwise , damage nasal space , opinion investigator might interfere ability absorb RX0041002 . 6 . Has severely traumatize mucosa sepsis nasal cavity . 7 . Has participate investigational study receive investigational drug within 30 day precede randomization . 8 . Is pregnant nursing mother . 9 . Has positive pregnancy test Screening Day 1 . 10 . Has history seizure , exception febrile seizure . 11 . Has glaucoma , symptomatic cardiovascular disease , moderate severe hypertension ( defined average SBP ≥160 mmHg average DBP ≥ 100 mmHg dose visit ) . 12 . Has know personal family history hereditary pseudocholinesterase deficiency . Study participant screen ask personal family history anesthetic reaction , anesthetic death , previous diagnosis psuedocholinesterase deficiency relative personally . Subjects identify pseudocholinesterase deficiency risk delay recovery certain anesthetic ( e.g . succinylcholine esterbased anesthetic ) . 13 . Has know personal family history pheochromocytoma . Study participant specifically ask treated pheochromocytoma previously family member diagnose pheochromocytoma ( since 10 % familial ) . 14 . Has know personal family history adrenal tumor . 15 . ECG abnormality judge clinically significant investigator . 16 . Has positive urine test result drug abuse ( amphetamine , barbiturate , cannabinoids , cocaine metabolite , opiates oxycodone ) Screening Day 1 17 . Hematocrit , WBC , platelet outside normal limit judge clinically significant investigator . 18 . Serum potassium outside normal limit judge clinically significant investigator . 19 . Serum ALT , AST , bilirubin exceed 2X ULN lab 's reference value . 20 . Evidence impair renal function base upon laboratory test investigator opinion . 21 . Clinical chemistry abnormality judge clinically significant investigator . 22 . Donation blood ( one pint great ) within four week prior administration study medication . 23 . Not suitable entry study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>